Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · May 8, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to see if a medication called fluvoxamine can help reduce the risk of delirium in older patients after they have non-heart-related surgeries. Delirium is a sudden change in mental function that can happen after surgery, and this study aims to understand if fluvoxamine can make a difference. The trial is still in the planning stages and is not yet recruiting participants.

To be eligible for this study, participants need to be English-speaking adults who are scheduled for elective surgeries that will require at least a two-day hospital stay. However, certain people may not qualify, such as those who have taken other investigational drugs recently, have a history of allergic reactions to fluvoxamine, or have particular health conditions. If you choose to participate, you can expect close monitoring and support throughout the study to help ensure your safety. This trial is an important step in exploring new ways to help older patients have better recovery experiences after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • English-speaking
• • elective non-cardiac or non-intracranial surgery requiring at least a 2-day hospital length of stay
• Exclusion Criteria:
• • Received investigational drug within the last 7 weeks
• • lack of capacity to provide informed consent
• • prior known intolerance or allergy to SSRIs or fluvoxamine
• • planned postoperative ventilation
• • drug or alcohol dependence
• • preoperative use of non-NSAID medications with drug-drug interactions of Class X (Avoid Combination) or D (Consider Therapy Modification)
• • risk of serotonin syndrome (St John's Wort, SSRIs, or TCA)